HEALTH CANADA REGULATION
DRUG SUBMISSION
POST MARKET SURVEILLANCEE
EXPEDITED REVIEWS
RISK AND SAFETY MANAGEMENT
100

What does NOC stand for?

Notice of Compliance

100

Purpose of a Master File (MF)?

Protects confidential business information?
100

What is post-market surveillance?

Monitoring drug safety after approval

100
What is ANDS?
Abbreviated New Drug Submission
100

Hc actions for risky drugs?

Label changes, recalls and withdrawals

200
What is a NHP?
Natural Health Product?
200

Number of Master Files Types?

5

200

Time hospital have to report ADR?

30 DAYS

200

What is NOC/c?

Approval with post market conditions

200

What is an ADR signal?

Potential safety issues from reports

300

Average drug review time in Canada?

6 months to 2 years

300

Role of Letter of Access (LoA)?

Allows HC to access MF information

300

What is HC vigilance?

Post market drug safety monitoring

300

what is an expedited review?

faster review for urgent needs

300

Why strict vaccine monitoring?

public trust and safety

400

Primary reason for regulatory delays in Canada?

Market Size & Later Submissions

400
When is a new MF needed?

Different Active Substance, synthesis or form

400

Serious adverse reaction percentage?

above 70%

400

Priority-reviewed drugs safety warning rate?

above 30%

400

How does HC communicate risks?

risk communication, recalls, black box warnings

500

What factors affect HC approval timelines?

strict policies, regulations and data access

500

Who submits an MF?

Manufacturer or authorized agent

500
What sources does HC use?

ADR reports, foreign data, literature etc.

500

What is the impact delayed approvals?

Delayed patient access, competitive disadvantage
500

What are examples of serious ADRs?

Hospitalization, life-threatening condition, death
M
e
n
u